Biogen stock (US09062X1037): Alzheimer’s focus after Leqembi setback and pipeline updates

Biogen remains in the spotlight after discontinuing its share of Leqembi commercialization and refocusing on other neurology and rare disease assets. Investors are weighing recent earnings, pipeline milestones and strategic shifts in Alzheimer’s and beyond.

Biogen is again drawing investor attention as the biotech group reshapes its Alzheimer’s strategy, pivots resources toward other neurology and rare disease assets, and works through the financial impact of slowing revenue from older multiple sclerosis drugs. Recent quarterly figures and pipeline news offer fresh insight into how the company is trying to stabilize growth and reposition itself in a competitive US biotech landscape, according to Biogen investor updates as of 04/24/2025 and coverage from Reuters as of 04/24/2025.

As of: 19.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Biogen Inc.
• Sector/industry: Biotechnology, neuroscience-focused pharmaceuticals
• Headquarters/country: Cambridge, Massachusetts, United States
• Core markets: United States, Europe, selected international markets
• Key revenue drivers: Multiple sclerosis therapies, spinal muscular atrophy treatment, biosimilars, newer neurology launches
• Home exchange/listing venue: Nasdaq (ticker: BIIB)
• Trading currency: US dollar (USD)

Biogen Inc.: core business model

Biogen’s core business model is built around researching, developing and commercializing therapies for neurological and neurodegenerative diseases. The company historically derived a large part of its sales from multiple sclerosis drugs such as Tecfidera and Tysabri, which helped establish Biogen as a major US biotech player, according to SEC Form 10-K as of 02/14/2025.

Over the past years, Biogen has sought to diversify away from its aging multiple sclerosis franchise by investing heavily in Alzheimer’s disease, amyotrophic lateral sclerosis, spinal muscular atrophy and rare diseases. The company’s strategy combines in-house research, licensing deals and partnerships to share development costs and reduce risk in large, high-uncertainty indications such as Alzheimer’s, as described in its strategic overview in the Biogen strategic update as of 03/18/2025.

Commercially, Biogen operates a hybrid model that integrates specialty sales forces, medical outreach and reimbursement negotiations with payers in key markets. The company focuses on high-value therapies that address serious, often debilitating neurological conditions where treatment options have historically been limited. This positioning allows Biogen to target premium pricing but also exposes it to regulatory and reimbursement scrutiny, particularly in the US, where payers closely assess the cost-effectiveness of novel treatments.

From a financial standpoint, Biogen’s revenue base has evolved from being centered on a few blockbuster multiple sclerosis therapies toward a more mixed portfolio. While legacy products remain important cash generators, competitive pressure from generics, biosimilars and alternative therapies has increased. Management has responded with cost-control measures, portfolio pruning and targeted investment in late-stage pipeline assets aimed at offsetting the decline of older products, according to commentary in the company’s quarterly results materials in Biogen Q1 2025 results as of 04/24/2025.

Main revenue and product drivers for Biogen Inc.

Biogen’s current revenue profile is anchored by therapies in multiple sclerosis, spinal muscular atrophy and biosimilars. Even though sales of some older multiple sclerosis drugs have declined due to generic competition and new rivals, these products continue to contribute a meaningful share of Biogen’s top line. In its annual report for the year ended December 31, 2024, the company highlighted that multiple sclerosis therapies remained a sizable, though shrinking, portion of revenue, as outlined in the SEC Form 10-K as of 02/14/2025.

In parallel, Biogen has developed newer neurology and rare disease assets, such as treatments for spinal muscular atrophy and certain biosimilars, which are designed to broaden the company’s revenue base beyond traditional multiple sclerosis drugs. These products typically serve specialized patient populations and require substantial investment in clinical development, regulatory submissions and market access negotiations, but can drive attractive margins if adoption meets expectations and competition remains manageable.

A key area of investor focus has been Biogen’s Alzheimer’s portfolio. The company originally pushed into the field with Aduhelm, a controversial therapy that received accelerated approval from the US Food and Drug Administration in 2021 but later saw limited commercial uptake and heightened scrutiny. Biogen subsequently collaborated with Eisai on Leqembi (lecanemab), another Alzheimer’s treatment that secured full FDA approval and represented a new growth opportunity. However, Biogen later chose to discontinue its participation in certain commercialization aspects of Leqembi to reallocate resources, a move covered in detail by Reuters as of 01/31/2024.

Beyond Alzheimer’s, Biogen maintains a pipeline of neuroscience and rare disease candidates at various stages of development. These include programs in depression, movement disorders and genetic conditions where unmet medical need is significant. Success in late-stage trials could provide future revenue pillars and reduce dependence on any single product or therapeutic area. That said, the timeline and probability of success for such candidates are inherently uncertain, and individual readouts can materially influence investor sentiment toward the stock, according to risk disclosures in the SEC Form 10-K as of 02/14/2025.

Industry trends and competitive position

Biogen operates in a competitive global biotechnology landscape where large US and international players are developing therapies across neurology, oncology, immunology and rare diseases. The neuroscience segment in particular has become more crowded as peers pursue Alzheimer’s, Parkinson’s disease and other neurodegenerative conditions. This environment pressures pricing and intensifies the race to bring differentiated, clinically meaningful products to market, as observed in sector analyses summarized by Financial Times healthcare coverage as of 03/05/2025.

Regulatory dynamics also play a critical role. The FDA’s evolving standards for approving Alzheimer’s therapies, including the balance between surrogate endpoints and clinical outcomes, affect how companies design trials and communicate benefit-risk profiles. Biogen’s experience with Aduhelm and its later partnership on Leqembi underscored how regulatory decisions, coverage policies from Medicare and public debate can significantly shape commercial prospects. This makes engagement with regulators, payers and the scientific community an ongoing strategic priority for the company.

Within this context, Biogen seeks to differentiate itself through deep expertise in neurology, long-standing relationships with specialists and a focus on diseases with high unmet need. However, it faces strong competition from large pharmaceutical groups and innovative biotechs targeting similar pathways. Access to capital, the ability to attract scientific talent and prudent allocation of research spending are important factors determining how well Biogen can sustain its edge as the field advances and new modalities, such as gene and cell therapies, gain momentum in the US and abroad.

Why Biogen Inc. matters for US investors

For US investors, Biogen represents exposure to the high-risk, high-uncertainty end of the healthcare sector, with a specific concentration in neurology and rare diseases. The stock is listed on Nasdaq and included in several biotech and healthcare indices, which means it can influence sector ETFs and broader sentiment toward innovative drug developers when major trial readouts or regulatory decisions occur, as noted in index documentation cited by Nasdaq data as of 04/30/2025.

Biogen’s results can also serve as a barometer for investor appetite toward Alzheimer’s and neurodegeneration research more broadly. Positive or negative surprises in clinical data from Biogen or its partners may ripple across peers pursuing similar targets, affecting valuations and capital flows into the space. In addition, changes in US health policy, drug pricing debates and Medicare coverage decisions for complex neurology drugs can have a disproportionate impact on Biogen’s outlook, making policy monitoring an important element of following the stock.

Another consideration for US investors is Biogen’s balance between mature cash-generating products and longer-dated pipeline assets. Cash flow from established therapies supports research spending, business development and potential shareholder returns, while pipeline outcomes drive long-term growth prospects. How management calibrates this balance—through cost management, licensing deals and portfolio priorities—may influence perceptions of risk and resilience in a sector where individual drugs often carry outsized importance for financial performance.

Conclusion

Biogen stands at a strategic crossroads as it adapts to pressure on legacy multiple sclerosis drugs and recalibrates its Alzheimer’s ambitions while preserving its long-standing focus on neurology and rare diseases. Recent financial reports and portfolio decisions highlight both the challenges of competing in a crowded biotech arena and the potential upside from successful late-stage programs. For US-focused market participants, the stock remains a prominent example of how regulatory, scientific and commercial factors intersect in high-stakes therapeutic areas, underlining the importance of close attention to trial updates, policy shifts and management’s capital allocation choices.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.